

Sakar Healthcare Delivers Strong Revenue Growth at 35% YoY

Mumbai, 7th November 2025 : Sakar Healthcare Ltd [NSE: SAKAR, with a research-driven API-integrated EU GMP approved oncology orals and injection manufacturing unit, has announced its un-audited financial results for the quarter and half year ended 30th September 2025.

Q2 & H1 FY26 Consolidated Financial Performance

Particulars (INR Lacs)	Q2FY26	Q2FY25	Y-o-Y	H1FY26	H1FY25	Y-o-Y
Revenue from Operations	5,756.04	4,277.81	34.6%	11,029.66	8,392.58	31.4%
Gross Profit	2,715.40	1,988.04		5,935.88	4,495.91	
<i>Gross Profit Margin (%)</i>	47%	46%		46%	46%	
EBITDA	1,135.39	1,150.12	-1.3%	2,405.97	2,220.01	8.4%
<i>EBITDA Margin (%)</i>	20%	27%		22%	26%	
Profit After Tax	453.98	479.63	-5.3%	921.11	720.83	27.8%

Business Highlights for Q2 & H1 FY26

- 49 agreements are in place with oncology products
 - Diverse business models: CDMO, CMO, Out-licensing
 - Covering product SKUs: 277
 - Business plan received: ~ INR 452 crores
- +80 dossiers submitted worldwide of which 11 Marketing Authorizations (registrations) received:
 - 6 - Europe & 5 from Emerging markets
- 21 APIs developed in-house
 - 16 with Written Confirmation
 - 7 lined up for CEP
- Received first patent with oncology product Imatinib
- R&D team actively involved in patent non-infringing product development for European partner

Commenting on the Results, Mr. Sanjay Shah, Managing Director & CEO said, Sakar Healthcare continued to maintain a stable financial performance during the year, supported by consistent growth in exports and an expanding product portfolio. The company's focus on operational efficiency and enhanced product mix contributed to sustained profitability. Strategic investments in the oncology vertical and modernization of facilities are expected to further strengthen revenue visibility and margin profile. With a balanced approach to growth, Sakar remains well-positioned to leverage emerging opportunities in regulated markets and deliver long-term value to its stakeholders.

About Sakar HealthCare Limited:

Established in 2004 and headquartered in Ahmedabad, Gujarat, Sakar Healthcare Limited is a publicly listed pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high-potent oncology products. Sakar's oncology division at Bavla represents a research-driven, API-integrated facility focused on developing and commercializing complex cytotoxic formulations and APIs, underscoring its commitment to innovation and quality. With an extensive global footprint across more than 60 countries, Sakar serves as a trusted partner to multinational pharmaceutical companies through CDMO, CRAMS, and technology transfer collaborations. Driven by its vision to deliver world-class healthcare solutions that make lives healthier and more meaningful, Sakar continues to expand its presence across regulated markets through strong R&D capabilities, regulatory excellence, and sustainable manufacturing practices rooted in green chemistry principles.

Contact Details

Sakar HealthCare Limited	Investor Relations: MUFG Intime India Private Limited
	
CIN - L24231GJ2004PLC043861	Mr. Nikunj Seth Ms. Sejal Bhattar +91 9773397958 +91 7666736666 nikunj.seth@in.mpms.mufg.com sejal.bhattar@in.mpms.mufg.com
Mr. Dharmesh Thaker CFO info@sakarhealthcare.com	

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.